Angiotensin IV suppresses inflammation in the brains of rats with chronic cerebral hypoperfusion.

INTRODUCTION: This study aimed to evaluate the influence of central angiotensin IV (Ang IV) infusion on chronic cerebral hypoperfusion (CCH)-related neuropathological changes including amyloid-β (Aβ), hyperphosphorylated tau (p-tau) and the inflammatory response.
MATERIALS AND METHODS: Rats with CCH received central infusion of Ang IV, its receptor AT4R antagonist divalinal-Ang IV or artificial cerebrospinal fluid for six weeks. During this procedure, the systolic blood pressure (SBP) was monitored, and the levels of Aβ42, p-tau and pro-inflammatory cytokines in the brain were detected.
RESULTS: Rats with CCH exhibited higher levels of Aβ42, p-tau and pro-inflammatory cytokines in the brain when compared with controls. Infusion of Ang IV significantly reduced the expression of pro-inflammatory cytokines in the brains of rats with CCH. Meanwhile, the reduction of pro-inflammatory cytokines levels caused by Ang IV was reversed by divalinal-Ang IV. During the treatment, the SBP in rats was not significantly altered.
CONCLUSION: This study demonstrates for the first time that Ang IV dose-dependently suppresses inflammation through AT4R in the brains of rats with CCH, which is independent from SBP. These findings suggest that Ang IV/AT4R may represent a potential therapeutic target for CCH-related neurological diseases.

Introduction

Chronic cerebral hypoperfusion (CCH) usually results from vascular and metabolic diseases including hypertension, diabetes and atherosclerosis, and is considered as a critical risk factor for both vascular dementia (VaD) and Alzheimer’s disease (AD).[1] Pathologically, CCH triggers the formation of amyloid-β (Aβ), tau hyperphosphorylation and the inflammatory response in the brain, and subsequently leads to white matter damage, neurodegeneration and cognitive impairments.[2] To date, there is no effective treatment for these CCH-related neuropathological changes in the brain.

Previously, the renin–angiotensin system (RAS) was identified as a crucial component of the circulatory system, functioning as a regulator of water and sodium homeostasis.[3] In the brain, independent local RAS has been found in several regions and structures, and is involved in the pathogenesis of several neurological diseases including ischaemic stroke, Parkinson’s disease, VaD and AD.[4-7] As an important component of the brain RAS, angiotensin IV (Ang IV) is reported to bind to its receptor AT4R and thus restore cognitive function following a variety of central insults, including CCH.[8,9] However, whether this hexapeptide has beneficial effects on CCH-related neuropathological changes is less well studied thus far.

In the present study, we hypothesized that exogenous Ang IV infusion might influence CCH-related neuropathological changes such as Aβ, hyperphosphorylated tau (p-tau) and the inflammatory response via a dose-dependent manner. To evaluate this hypothesis, a CCH rat model induced by bilateral common carotid artery (CCA) ligation was employed. For the first time, we showed that Ang IV dose-dependently suppressed inflammation through AT4R in the brains of rats with CCH, whereas the levels of Aβ and p-tau were unaffected. This beneficial effect of Ang IV seemed to be independent from systolic blood pressure (SBP). Taken together, these findings suggest that Ang IV/AT4R may represent a potential therapeutic target for CCH-related neurological diseases.

Materials and methods

Reagents

Ang IV and its receptor antagonist divalinal-Ang IV were synthesized by Nanjing Maoyuan Biological Technology Company. They were dissolved in an artificial cerebrospinal fluid (aCSF, composition in mM: NaCl 130, KCl 2.99, CaCl2 0.98, MgCl2·6H2O 0.8, NaHCO3 25, Na2HPO4·12H2O 0.039 and NaH2PO4·2H2O 0.46) as described.[4]

Animals

A total of 56 male wistar rats (10–12 weeks old, 300–350 g) were included in this study. They were purchased from the Experimental Animals Center of Nanjing Medical University, were housed in a standard animal room with a 12 h light/dark cycle, and were given free access to food and water. The Animal Care and Management Committee of Nanjing First Hospital approved the whole study protocol. All animal experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, and were reported in accordance with the Animal research: Reporting of in vivo experiments (ARRIVE) guidelines.[10] The number of animals used was minimized within the constraints of statistical power.

Surgical procedure

The rat model of CCH was established by bilateral CCA ligation surgery, as previously described.[6] Rats were anaesthetized with 10% chloral hydrate and the bilateral CCAs were isolated through a ventral midline incision as described.[6] Afterward, the bilateral CCAs were ligated with a 4-0 surgical silk suture in the CCH group, whereas they were not ligated in controls. Throughout the procedure, body temperature was monitored with a rectal probe and maintained in the range of 37.0 ± 0.5°C with a heating pad.

Treatment

Eight weeks after bilateral CCA ligation surgery, rats were anaesthetized with 10% chloral hydrate and placed in a stereotactic frame. The scalp was reflected under sterile surgical conditions. A brain-infusion cannula (Brain Infusion Kit 2; ALZET Inc.) coupled via vinyl tubing to an osmotic pump (Model 2006; ALZET Inc.) was implanted into the third cerebral ventricle by surgeons who were blinded to the experimental groups. Osmotic pumps were placed subcutaneously between the scapulae and used to infuse two doses of Ang IV (20 nM, 0.15 µl/h and 100 nM, 0.15 µl/h), divalinal-Ang IV (500 nM, 0.15 µl/h) or aCSF (0.15 µl/h) into the third cerebral ventricle, lasting for six weeks. Following this surgery, the wounds were carefully closed with sutures. The dose and route of administration for Ang IV were chosen based on a previous study by Paris et al.[11]

Blood pressure measurement

In this study, SBP was measured by a tail cuff method using a non-invasive blood pressure analyser (BP-2000, Visitech Systems, Inc.), as previously described.[12] Measurements were performed on week 0 (before surgery), week 8 (eight weeks after bilateral CCAs ligation surgery) and week 14 (six weeks after treatment) in rats between 08:00 a.m. and 12:00 a.m. Each measurement was performed three times to obtain a mean SBP. It is worth noting that the SBP was not significantly affected by bilateral CCA ligation surgery, osmotic pump implantation, or infusion of Ang IV (20 nM or 100 nM) or divalinal-Ang IV (500 nM).

Brain tissue preparation

Rats were killed under deep anaesthesia following six weeks of treatment. They (n = 8 per group) were perfused transcardially with 0.9% saline (pH 7.4), after which brains were removed and stored in liquid nitrogen until use.

Enzyme-linked immunosorbent assay

For the measurement of pro-inflammatory cytokines, brains were lysed as described.[13] The protein levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and IL-12 were measured by specific enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems Inc.). For the measurement of Aβ42, the cerebral cortex and hippocampus were separately homogenized in 10 volumes of tris-buffered saline containing 5 mM ethylene diamine tetraacetic acid (EDTA), phosphatase inhibitor, EDTA-free protease inhibitor cocktail and 2 mM 1,10-phenanthroline at 4°C. The homogenate was centrifuged for 1 h at 4°C. Supernatants were collected and the levels of Aβ42 were detected by a specific ELISA kit. For the measurement of p-tau (Thr181) levels, the cerebral cortex and hippocampus were separately homogenized and lysed as previously described.[14] The levels of p-tau (Thr181) were assessed by a specific ELISA kit.

Statistical analysis

Data were analysed using GraphPad Prism 6 (GraphPad Software, Inc.). One-way analysis of variance (ANOVA) followed by Tukey’s post hoc test was employed to analyse differences among groups. Statistical power was estimated using STPLAN version 4.3 software. Data are expressed as mean ± SD. P < 0.05 was considered significant.

Results

Ang IV does not influence Aβ levels in the brains of rats with CCH

As demonstrated by Figure 1(a) and (b), rats with CCH exhibited higher levels of Aβ42 in the cerebral cortex and hippocampus when compared with controls (for cerebral cortex: F (4, 35) = 31.41, 629.3 ± 86.4 vs 115.7 ± 21.2 pg/mg wet tissue, P < 0.05; for hippocampus: F (4, 35) = 24.49, 966.8 ± 155.4 vs 123.1 ± 25.9 pg/mg wet tissue, P < 0.05). Ang IV infusion (20 nM or 100 nM) did not alter the levels of Aβ42 in the cerebral cortex of rats with CCH (Figure 1(a)). Meanwhile, the levels of Aβ42 in the hippocampus of controls were not significantly affected by Ang IV infusion (20 nM or 100 nM, Figure 1(b)).

Figure 1.

Angiotensin IV does not influence amyloid-β levels in brains of rats with chronic cerebral hypoperfusion. (a) The levels of amyloid-β42 in the cerebral cortex were detected by enzyme-linked immunosorbent assay. (b) The levels of amyloid-β42 in the hippocampus were detected by enzyme-linked immunosorbent assay. Data were analysed by one-way analysis of variance followed by Tukey’s post hoc test. Columns represent mean ± SD. n = 8 per group.

*P < 0.05 versus controls.

Aβ: amyloid-β; aCSF: artificial cerebrospinal fluid; Ang IV: angiotensin IV; CCH: chronic cerebral hypoperfusion.

Ang IV does not affect p-tau levels in the brains of rats with CCH

As illustrated by Figure 2(a) and (b), the levels of p-tau in the cerebral cortex and hippocampus of rats with CCH were markedly higher than those of controls (for cerebral cortex: F (4, 35) = 30.42, 22.3 ± 3.6 vs 1.9 ± 0.3 ng/mg wet tissue, P < 0.05; for hippocampus: F (4, 35) = 28.24, 40.9 ± 8.4 vs 3.2 ± 0.8 ng/mg wet tissue, P < 0.05). Infusion of Ang IV (20 nM or 100 nM) did not affect the levels of p-tau in the cerebral cortex of rats with CCH (Figure 2(a)). Meanwhile, p-tau levels in the hippocampus of rats with CCH were not significantly affected by infusion of Ang IV (20 nM or 100 nM, Figure 2(b)).

Figure 2.

Angiotensin IV does not affect p-tau levels in brains of rats with chronic cerebral hypoperfusion. (a) The levels of p-tau (Thr181) in the cerebral cortex were detected by enzyme-linked immunosorbent assay. (b) The levels of p-tau (Thr181) in the hippocampus were detected by enzyme-linked immunosorbent assay. Data were analysed by one-way analysis of variance followed by Tukey’s post hoc test. Columns represent mean ± SD. n = 8 per group. *P < 0.05 vs controls. aCSF: artificial cerebrospinal fluid; Ang IV: angiotensin IV; CCH: chronic cerebral hypoperfusion.

Ang IV suppresses inflammation in the brains of rats with CCH

As demonstrated by Figure 3(a)–(d), rats with CCH displayed higher protein levels of pro-inflammatory cytokines including TNF-α (F (6, 49) = 35.64, 386.2 ± 42.1 vs 76.9 ± 11.7 pg/mg wet tissue, P < 0.05), IL-1β (F (6, 49) = 27.43, 783.4 ± 128.3 vs 215.7 ± 38.5 pg/mg wet tissue, P < 0.05), IL-6 (F (6, 49) = 38.88, 1124.5 ± 158.2 vs 94.6 ± 18.5 pg/mg wet tissue, P < 0.05) and IL-12 (F (6, 49) = 39.24, 152.7 ± 32.6 vs 34.8 ± 7.3 pg/mg wet tissue, P < 0.05) in the brain when compared with controls. Infusion of Ang IV (20 nM or 100 nM) significantly reduced the protein levels of TNF-α, IL-1β, IL-6 and IL-12 in the brains of rats with CCH (Figure 3(a)–(d), all P < 0.05). Meanwhile, the reduction of TNF-α, IL-1β, IL-6 and IL-12 protein levels caused by Ang IV (100 nM) in the brains of rats with CCH was completely reversed by infusion of divalinal-Ang IV (500 nM, Figure 3(a)–(d), all P < 0.05). Of note, neither osmotic pump implantation nor divalinal-Ang IV (500 nM) infusion significantly influenced the protein levels of TNF-α, IL-1β, IL-6 or IL-12 in the brains of rats with CCH (Figure 3(a)–(d)).

Figure 3.

Angiotensin IV suppresses inflammation in the brains of rats with chronic cerebral hypoperfusion. (a) The protein levels of tumour necrosis factor-α in the brain were detected by enzyme-linked immunosorbent assay. (b) The protein levels of interleukin-1β in the brain were detected by enzyme-linked immunosorbent assay. (c) The protein levels of interleukin-6 in the brain were detected by enzyme-linked immunosorbent assay. (d) The protein levels of interleukin-12 in the brain were detected by enzyme-linked immunosorbent assay. Data were analysed by one-way analysis of variance followed by Tukey’s post hoc test. Columns represent mean ± SD. n = 8 per group.

*P < 0.05 versus controls. #P < 0.05 versus CCH+aCSF group. &P < 0.05 versus CCH+Ang IV (100 nM) group.

aCSF: artificial cerebrospinal fluid; Ang IV: angiotensin IV; CCH: chronic cerebral hypoperfusion; IL: interleukin; TNF: tumour necrosis factor.

Discussion

Emerging evidence has indicated that CCH is associated with an increased inflammatory response in the brain.[15,16] This may be a consequence of Aβ formation and tau hyperphosphorylation induced by CCH.[17,18] Although the inflammatory response is crucial for the brain to remove senescent cells and extrinsic pathogenic substances, long-lasting neuroinflammation is toxic to neurons and synapses, and thus contributes to neurodegeneration, white matter damage and cognitive impairments.[19-22] In this study, we confirmed previous findings by showing higher protein levels of pro-inflammatory cytokines including TNF-α, IL-1β, IL-6 and IL-12 in the brains of rats with CCH. More importantly, we revealed for the first time that Ang IV suppressed this inflammatory response via a dose-dependent manner, which was independent from SBP. The anti-inflammatory property of Ang IV has been previously validated under various conditions. In a rat model of myocardial ischaemia-reperfusion, Park and colleagues found that Ang IV suppressed the inflammatory response in cardiomyocytes and thus exerted cardioprotective effects.[23] In a previous study by Kong et al., treatment with a medium dose of Ang IV markedly reduced the expression of pro-inflammatory cytokines in a mouse model of abdominal aortic aneurysm induced by angiotensin II.[24] More recently, in a mouse model of AD, Royea and colleagues revealed that the anti-inflammatory effect of losartan was actually achieved by Ang IV.[25] Meanwhile, in this study, we also revealed that the anti-inflammatory property of Ang IV was mediated by AT4R, and this finding was consistent with previous observations from other groups.[23-25] Nevertheless, Kong and colleagues showed that Ang IV may potentially affect the expression of AT2R.[24] Meanwhile, recent evidence suggests that Ang IV may exert its function via hepatocyte growth factor (HGF)/c-Met signalling.[26] Interestingly, activation of AT2R or HGF/c-Met signalling was revealed to suppress the inflammatory response in different tissues.[27-30] Therefore, whether AT2R or HGF/c-Met signalling was involved in the anti-inflammatory properties of Ang IV under the context of CCH deserves further investigation in the future.

Lastly, some minor issues should be mentioned. First, in the present study, we did not elucidate the precise cellular mechanisms by which Ang IV suppressed inflammation in the brain with CCH. Since AT4R has been identified in rat astrocytes,[31] we speculated that Ang IV may exert its anti-inflammatory function by inhibition of the astrocyte-mediated inflammatory response. This speculation needs to be verified in the future. Second, in this study, although Ang IV infusion significantly suppressed inflammation in the brains of rats with CCH, it did not affect AD-like neuropathology including Aβ42 and p-tau. These findings were in accordance with a previous study from Royea and colleagues showing that Ang IV did not influence AD-like neuropathology in a mouse model of AD,[25] suggesting that this hexapeptide may not be involved in the formation or degradation of these neuropathological changes. However, it is also possible that the six-week central infusion of Ang IV is not enough to cause obvious alterations in Aβ42 and p-tau levels. Unfortunately, the limited working duration of osmotic pumps suitable for rats (maximum six weeks, Model: 2006D) prevented us from observing longer effects of Ang IV. Third, we delivered Ang IV to the brain via an intracerebroventricular infusion strategy because this peptide cannot readily penetrate the blood brain barrier (BBB) and is rapidly degraded by several proteases in the peripheral tissues.[32] This property largely restricts the application of Ang IV in animal and clinical research. In view of this fact, artificial synthetic Ang IV analogues with oral efficacy, extended half-life and increased BBB penetrability such as Nle[1]-AngIV and Dihexa will be employed in our future studies.[33,34]

In conclusion, this study provided the first evidence that Ang IV dose-dependently suppresses inflammation through AT4R in the brains of rats with CCH, whereas the levels of Aβ42 and p-tau were unaffected. Meanwhile, the anti-inflammatory effect of Ang IV seemed to be independent from SBP. These findings suggest that Ang IV/AT4R may represent a potential therapeutic target for CCH-related neurological diseases.